Checked
Teva Pharmaceutical Industries Ltd
NYSE: TEVA · Pharmaceutical Preparations · Tel Aviv, Israel
- Revenue
- $17.26B
- +4.3% vs. prior year
- Net income
- $1.41B
- 8.2% net margin
- Total assets
- $40.75B
- Diluted EPS
- $1.21
Company details
As reported to the SEC
- SEC CIK
- 818686
- Stock
- NYSE: TEVA
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- Headquarters
- Tel Aviv, Israel
- Fiscal year end (SEC record)
- December 31
- Filer status
- Large accelerated filer
- Last annual report
- 02/03/2026
- Last quarterly report
- 07/29/2026
Formerly: TEVA PHARMACEUTICAL INDUSTRIES LIMITED (until 01/16/2001)
Annual financials
U.S. dollars, as tagged in each annual report's XBRL data. Later restatements replace earlier numbers. Select a date to open the filing.
| Fiscal year ended | 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 |
|---|---|---|---|---|---|
| Revenue | $17.26B | $16.54B | $15.85B | $14.93B | $15.88B |
| Gross profit | $8.94B | $8.06B | $7.64B | $6.97B | $7.59B |
| Operating income | $2.16B | -$303M | $433M | -$2.2B | $1.72B |
| Net income | $1.41B | -$1.64B | -$559M | -$2.45B | $417M |
| Diluted earnings per share | $1.21 | -$1.45 | -$0.50 | -$2.20 | $0.38 |
| Research and development | $1.01B | $998M | $953M | $98M | $967M |
| Total assets | $40.75B | $39.33B | $43.48B | $44.01B | $47.67B |
| Total liabilities | $32.83B | $33.61B | $35.35B | $35.41B | $36.42B |
| Shareholders' equity | $7.91B | $5.37B | $7.51B | $7.8B | $10.28B |
| Cash and cash equivalents | $3.56B | $3.3B | $3.23B | $2.8B | $2.17B |
| Cash from operations | $1.65B | $1.25B | $1.37B | $1.59B | $798M |
| Capital expenditures | Not reported | Not reported | Not reported | $548M | $562M |
Federal and state records filed under the name Teva Pharmaceutical Industries Ltd
Matched by the company name and by the subsidiary names it lists in SEC filings and other public records, after removing endings like Inc., Corp. and Holdings. Records marked Subsidiary were filed under a subsidiary name. A subsidiary that is not listed in those records is not included, and an unrelated business with the same name can appear.
Work visa sponsorship
Certified H-1B and PERM green card filings with the Department of Labor
| Employer on filing | H-1B | PERM |
|---|---|---|
| Norton Healthcare Inc.Subsidiary · Louisville, KY | 11 | 1 |
| Teva Pharmaceuticals USA, Inc.Subsidiary · Parsipanny, NJ | 7 | 3 |
FDA recalls
Latest 10 of 281 recalls of food, drugs and devices
Swipe the table sideways to see more columns.
Drug shortages
Products this company makes or markets that are on the FDA drug shortage list
| Drug | Status |
|---|---|
| Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet | Current |
| Azacitidine Injection | Current |
| Carboplatin Injection | Current |
| Clonazepam Tablet | Current |
| Hydromorphone Hydrochloride Injection | Current |
| Hydroxocobalamin Injection | Current |
| Lisdexamfetamine Dimesylate Capsule | Current |
| Methotrexate Sodium Injection | Current |
| Methylphenidate Hydrochloride Tablet, Extended Release | Current |
| Streptozocin Powder, For Solution | Current |
| Adalimumab-ryvk Kit | To Be Discontinued |
| Allopurinol Tablet | To Be Discontinued |
Trucking registrations
Motor carrier registrations with the Federal Motor Carrier Safety Administration
Swipe the table sideways to see more columns.
| Carrier | USDOT | Power units |
|---|---|---|
| Norton Healthcare IncSubsidiary · Louisville, KY | 3428308 | 5 |
Subsidiaries
27 companies that Teva Pharmaceutical Industries Ltd owns or controls, as listed in its SEC annual report (Exhibit 21), GLEIF ownership records or USAspending
| Subsidiary | Listed in |
|---|---|
| Actavis Group PTC ehf | SEC 10-K |
| Actavis Pharma Holding 4 ehf | SEC 10-K |
| Anda Inc. | SEC 10-K |
| Arrow International Limited | SEC 10-K |
| Mepha Pharma AG | SEC 10-K |
| Merckle GmbH | SEC 10-K |
| Norton Healthcare Limited | SEC 10-K |
| Pliva Hrvatska d.o.o. | SEC 10-K |
| Ratiopharm GmbH | SEC 10-K |
| Salomon, Levin & Elstein Ltd. | SEC 10-K |
| TAPI NL B.V. | SEC 10-K |
| Teva Actavis Holding B.V. | SEC 10-K |
| Teva Biotech GmbH | SEC 10-K |
| Teva Canada Limited | SEC 10-K |
| Teva Capital Services Switzerland GmbH | SEC 10-K |
| Teva Czech Industries s.r.o | SEC 10-K |
| Teva Finance Services II B.V. | SEC 10-K |
| Teva Health GmbH | SEC 10-K |
| Teva Italia S.r.l | SEC 10-K |
| Teva Limited Liability Company | SEC 10-K |
| Teva Operations Poland Sp. Z.o.o. | SEC 10-K |
| Teva Pharma S.L.U | SEC 10-K |
| Teva Pharmaceuticals Finance Netherlands B.V. | SEC 10-K |
| Teva Pharmaceuticals International GmbH | SEC 10-K |
| Teva Pharmaceuticals USA, Inc. | SEC 10-K |
| Teva Sant SAS | SEC 10-K |
| Teva UK Limited | SEC 10-K |
Recent filings
138 recent filings on record; insider ownership forms (3, 4, 5 and 144) are not listed here
Swipe the table sideways to see more columns.
| Form | Filed | Period |
|---|---|---|
| 8-KMaterial agreement, New debt or obligation | 09/16/2026 | 09/16/2026 |
| 8-KOther events | 09/14/2026 | 09/14/2026 |
| 8-A12B/ASEC filing | 09/14/2026 | None |
| 25-NSEExchange notice of removal from listing (can be one bond or share class) | 09/14/2026 | None |
| 424B5Prospectus supplement | 09/11/2026 | None |
| 8-KRegulation FD disclosure, Other events | 09/11/2026 | 09/09/2026 |
| FWPFree writing prospectus | 09/10/2026 | None |
| FWPFree writing prospectus | 09/10/2026 | None |
| 424B5Prospectus supplement | 09/08/2026 | None |
| 8-KOther events | 09/03/2026 | 09/03/2026 |
| 8-KChange to shareholder rights | 09/03/2026 | 08/31/2026 |
| F-6 POSSEC filing | 07/29/2026 | None |
| 10-QQuarterly report | 07/29/2026 | 06/30/2026 |
| 8-KResults of operations | 07/29/2026 | 07/29/2026 |
| 8-KShareholder vote results | 05/28/2026 | 05/28/2026 |
| 10-QQuarterly report | 04/29/2026 | 03/31/2026 |
| 8-KResults of operations, Regulation FD disclosure | 04/29/2026 | 04/29/2026 |
| DEFA14AAdditional proxy materials | 03/31/2026 | None |
| ARSAnnual report to shareholders | 03/31/2026 | 12/31/2025 |
| DEF 14AProxy statement | 03/31/2026 | 05/28/2026 |
124 insider ownership reports (Forms 3, 4, 5 and 144) were filed about Teva Pharmaceutical Industries Ltd in the last 12 months. They list trades by officers, directors and large holders; see them on SEC EDGAR.
Other pharmaceutical preparations
Swipe the table sideways to see more columns.
| Company | Headquarters | Revenue | Net income |
|---|---|---|---|
| Johnson & JohnsonJNJ | New Brunswick, NJ | $94.19B | $26.8B |
| Eli Lilly & CoLLY | Indianapolis, IN | $65.18B | $20.64B |
| Merck & Co., Inc.MRK | Rahway, NJ | $65.01B | $18.25B |
| Pfizer IncPFE | New York, NY | $62.58B | $7.77B |
| AbbVie Inc.ABBV | North Chicago, IL | $61.16B | $4.23B |
| Astrazeneca PLCAZN | Cambridge, United Kingdom | $58.74B | $10.22B |
| Bristol Myers Squibb CoBMY | Princeton, NJ | $48.19B | $7.05B |
| Abbott LaboratoriesABT | Abbott Park, IL | $44.33B | $6.52B |
Profile refreshed Oct 26, 2026; financials refreshed Oct 22, 2026.
Frequently asked questions
- What is Teva Pharmaceutical Industries Ltd's CIK number?
- Teva Pharmaceutical Industries Ltd's SEC Central Index Key (CIK) is 818686.
- What is Teva Pharmaceutical Industries Ltd's stock ticker?
- Teva Pharmaceutical Industries Ltd trades as NYSE: TEVA.
- What was Teva Pharmaceutical Industries Ltd's revenue?
- Teva Pharmaceutical Industries Ltd reported revenue of $17.26B for the fiscal year ended Dec 31, 2025, +4.3% from the year before.
- When does Teva Pharmaceutical Industries Ltd's fiscal year end?
- Teva Pharmaceutical Industries Ltd's fiscal year end on file with the SEC is December 31; its most recent fiscal year ended Dec 31, 2025.
- Where is Teva Pharmaceutical Industries Ltd headquartered?
- Teva Pharmaceutical Industries Ltd's principal executive office on file with the SEC is in Tel Aviv, Israel.
- What companies does Teva Pharmaceutical Industries Ltd own?
- Teva Pharmaceutical Industries Ltd lists 27 subsidiaries in its SEC filings and other public records, including Actavis Group PTC ehf, Actavis Pharma Holding 4 ehf, Anda Inc.
- Does Teva Pharmaceutical Industries Ltd sponsor H-1B visas?
- Department of Labor records show 18 certified H-1B filings and 4 certified PERM filings under the name Teva Pharmaceutical Industries Ltd.
- Has Teva Pharmaceutical Industries Ltd had any FDA recalls?
- The FDA lists 281 recalls with Teva Pharmaceutical Industries Ltd as the recalling firm. The latest started Aug 24, 2026.
Source: U.S. Securities and Exchange Commission, EDGAR submissions and XBRL company facts · Last updated 10/26/2026